SYDNEY—Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.

CSL shares are down roughly 40% since acquiring Vifor in August 2022, an iron deficiency and kidney disease business and the largest acquisition in its history. However, several other factors have ...

Aug 19 (Reuters) - Australian biotech giant CSL (CSL.AX), opens new tab said on Tuesday it plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by the end of ...